2009/03/01 by Pierre Miossec · 28 citations
Immunology and Microbiology · Medicine · #Autoimmune Bullous Skin Diseases #Bioinformatics #Biology #Disease #Gene #Genetics #Human disease #Immunodeficiency and Autoimmune Disorders #Immunology #Inflammation #Inflammatory bowel disease #Interleukin 17 #Internal medicine #Medicine #Psoriasis #Psoriasis: Treatment and Pathogenesis #Rheumatoid arthritis
paper · doi:10.1002/eji.200839088
published in European Journal of Immunology 39(3), 667-669 (Wiley)
openalex publication_date 2009/03/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05
The discovery of IL-17 and of the Th17 pathway has been a step in the classification of human diseases. Th17 targeting appears rather straightforward in diseases associated with inflammation and matrix destruction, such as rheumatoid arthritis, psoriasis, and Crohn's disease. In other conditions where IL-17 is expressed and Th17 activated, it is unclear whether this is a primary or secondary event, making the use of Th17 inhibitors less obvious.